iRadimed Corporation (IRMD) To Go Ex-Dividend on August 14th

iRadimed Corporation (NASDAQ:IRMDGet Free Report) declared a quarterly dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be given a dividend of 0.20 per share by the medical equipment provider on Friday, August 28th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 14th.

iRadimed has a payout ratio of 40.2% meaning its dividend is sufficiently covered by earnings.

iRadimed Price Performance

iRadimed stock opened at $90.86 on Friday. iRadimed has a 12-month low of $57.83 and a 12-month high of $107.90. The stock has a market capitalization of $1.16 billion, a PE ratio of 50.76 and a beta of 0.90. The firm has a 50 day simple moving average of $94.54 and a 200-day simple moving average of $95.70.

iRadimed (NASDAQ:IRMDGet Free Report) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, topping the consensus estimate of $0.44 by $0.02. The firm had revenue of $20.47 million for the quarter, compared to analysts’ expectations of $20.35 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, analysts forecast that iRadimed will post 1.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, iRadimed presently has an average rating of “Buy” and a consensus target price of $120.00.

View Our Latest Report on iRadimed

iRadimed Company Profile

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

See Also

Dividend History for iRadimed (NASDAQ:IRMD)

Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.